PMID- 24246692 OWN - NLM STAT- MEDLINE DCOM- 20140317 LR - 20220331 IS - 1873-5835 (Electronic) IS - 0145-2126 (Linking) VI - 38 IP - 2 DP - 2014 Feb TI - Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis. PG - 170-5 LID - S0145-2126(13)00374-3 [pii] LID - 10.1016/j.leukres.2013.10.019 [doi] AB - Chronic lymphocytic leukemia (CLL) patients may acquire new chromosome abnormalities during the course of their disease. Clonal evolution (CE) has been detected by conventional chromosome banding (CBA), several groups also confirmed CE with fluorescence in situ hybridization (FISH). At present, there are minimal prospective data on CE frequency determined using a combination of both methods. Therefore, the aim of our study was to prospectively assess CE frequency using a combination of FISH and CBA after stimulation with CpG oligonucleotides and interleukin-2. Between 2008 and 2012, we enrolled 140 patients with previously untreated CLL in a prospective trial evaluating CE using FISH and CBA after stimulation. Patients provided baseline and regular follow-up peripheral blood samples for testing. There was a median of 3 cytogenetic examinations (using both methods) per patient. CE was detected in 15.7% (22/140) of patients using FISH, in 28.6% (40/140) using CBA, and in 34.3% (48/140) of patients by combining both methods. Poor-prognosis CE (new deletion 17p, new deletion 11q or new complex karyotype) was detected in 15% (21/140) of patients and was significantly associated with previous CLL treatment (p=0.013). CBA provides more complex information about cytogenetic abnormalities in CLL patients than FISH and confirms that many patients can acquire new abnormalities during the course of their disease in a relatively short time period. CI - Copyright (c) 2013 Elsevier Ltd. All rights reserved. FAU - Brejcha, Martin AU - Brejcha M AD - Department of Hematology, Hospital Novy Jicin, Czech Republic. FAU - Stoklasova, Martina AU - Stoklasova M AD - Laboratory of Medical Genetics - Department of Cytogenetics, AGEL Research and Training Institute - Novy Jicin Branch, AGEL Laboratories, Czech Republic. FAU - Brychtova, Yvona AU - Brychtova Y AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Panovska, Anna AU - Panovska A AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Stepanovska, Kristina AU - Stepanovska K AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Vankova, Gabriela AU - Vankova G AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Plevova, Karla AU - Plevova K AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic. FAU - Oltova, Alexandra AU - Oltova A AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. FAU - Horka, Katerina AU - Horka K AD - Laboratory of Medical Genetics - Department of Cytogenetics, AGEL Research and Training Institute - Novy Jicin Branch, AGEL Laboratories, Czech Republic. FAU - Pospisilova, Sarka AU - Pospisilova S AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic. FAU - Mayer, Jiri AU - Mayer J AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic. FAU - Doubek, Michael AU - Doubek M AD - Department of Internal Medicine - Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Electronic address: mdoubek@fnbrno.cz. LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131029 PL - England TA - Leuk Res JT - Leukemia research JID - 7706787 RN - 0 (CPG-oligonucleotide) RN - 0 (Interleukin-2) RN - 0 (Oligodeoxyribonucleotides) SB - IM MH - Adult MH - Aged MH - *Chromosome Banding MH - *Clonal Evolution MH - Female MH - Humans MH - *In Situ Hybridization, Fluorescence MH - Interleukin-2/pharmacology MH - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*pathology MH - Lymphocyte Activation/drug effects MH - Male MH - Middle Aged MH - Oligodeoxyribonucleotides/pharmacology MH - Prospective Studies OTO - NOTNLM OT - Chronic lymphocytic leukemia OT - Clonal evolution OT - CpG oligonucleotides OT - Cytogenetics OT - Fluorescence in situ hybridization OT - Interleukin-2 EDAT- 2013/11/20 06:00 MHDA- 2014/03/19 06:00 CRDT- 2013/11/20 06:00 PHST- 2013/08/31 00:00 [received] PHST- 2013/10/20 00:00 [revised] PHST- 2013/10/22 00:00 [accepted] PHST- 2013/11/20 06:00 [entrez] PHST- 2013/11/20 06:00 [pubmed] PHST- 2014/03/19 06:00 [medline] AID - S0145-2126(13)00374-3 [pii] AID - 10.1016/j.leukres.2013.10.019 [doi] PST - ppublish SO - Leuk Res. 2014 Feb;38(2):170-5. doi: 10.1016/j.leukres.2013.10.019. Epub 2013 Oct 29.